Phase I/II study of bisantrene in childhood cancer: a report from the Childrens Cancer Study Group.

Abstract

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respectively. The dose limiting toxicities were hepatic and hematologic. One patient with ALL achieved a complete remission and partial responses were observed in three patients with soft-tissue sarcomas. The data indicate that bisantrene, at the doses and schedule used in this study, has limited antitumor activity in pretreated children with cancer.

• Authors: N Movassaghi, W A Krivit, M D Krailo, G D Hammond
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 16 Issue 5 Pg. 333-6 ( 1988) ISSN: 0098-1532 [Print] United States
• PMID: 3054454 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anthracenes
• bisantrene

Topics

• Adolescent
• Adult
• Anthracenes (therapeutic use)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Infant
• Leukemia (drug therapy)
• Male